Dananberg Jamie 4

What Happened Jamie Dananberg, Chief Medical Officer of Annexon, received two compensation awards on February 19, 2026: 56,250 restricted stock units (RSUs) and 225,000 derivative awards (option-style), both reported as acquired at $0. These are grants of equity compensation (not open-market purchases or sales) and had no cash purchase price at grant.

Key Details

• Transaction date: February 19, 2026; Form 4 filed February 23, 2026 (filed within required two business days).
• Awards: 56,250 RSUs (reported at $0) and 225,000 derivative/option-style awards (reported at $0).
• Vesting (footnotes):
  • RSUs: 1/3 vest annually on Feb 19, starting Feb 19, 2027, subject to continued service. (Footnote F1)
  • Derivative/option: 1/48th vests monthly beginning Feb 19, 2026; fully vested on the 4th anniversary (Feb 19, 2030) subject to continued service. (Footnote F2)
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No sales, 10b5-1 plan, tax-withholding event, or other special codes were indicated in the excerpt.

Context These grants are standard equity compensation for executives — RSUs deliver shares upon vesting and the derivative award vests over time (not an immediate exercise or cash transaction). Because these are awards rather than open-market purchases or sales, they reflect compensation policy rather than a direct insider market signal.